Business
Glenmark introduces higher strength (400 mg) of FabiFlu(R) to reduce the pill burden of COVID-19 treatment
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India. The higher strength […]